PALIVIZUMAB PROFILAKSA RSV INFEKCIJE

Of all infants,147 (55.0%) were enrolled for prematurity only, 7 (2.6%) for bronchopulmonary dysplasia/ chronic lung disease (BPD/CLD), 115 (43.0% ) for congenital heart disease (CHD), and 5 (1.8%) for other reasons; 129 (46.3%) infants in total were born before 33 weeks. Case control study of the r...

Full description

Saved in:
Bibliographic Details
Published in:Acta medica Saliniana 2017-01, Vol.47, p.5
Main Authors: Ćosićkić, Almira, Ibrahimović, Jasminka, Čikarić, Amela
Format: Article
Language:Bosnian
Subjects:
Cardiovascular disease
Congenital diseases
Disease prevention
Hospitalization
Immunotherapy
Infections
Infectious diseases
Monoclonal antibodies
Newborn babies
Pediatrics
Respiratory syncytial virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Of all infants,147 (55.0%) were enrolled for prematurity only, 7 (2.6%) for bronchopulmonary dysplasia/ chronic lung disease (BPD/CLD), 115 (43.0% ) for congenital heart disease (CHD), and 5 (1.8%) for other reasons; 129 (46.3%) infants in total were born before 33 weeks. Case control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Lacaze-Masmonteil T, Roze JC, Fauroux B. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
ISSN:0350-364X
1840-3956
DOI:10.5457/413